mABs to Microcarriers: Applying Lessons Learned from Large-Scale Recombinant Protein Production to Advance Allogeneic Cell Therapy Manufacturing
Time: 12:30 pm
day: Day One Track B AM
Details:
- Allogeneic cell therapy manufacturing is currently where monoclonal antibody (mAB) manufacturing was 35 years ago: too expensive and unable to meet large market demands
- The breakthroughs that enabled commercial mAB manufacturing will be highlighted, including those that relied on extensive cell line adaptation. Similar breakthroughs are needed for allogeneic cell therapy manufacturing but will not rely on extensive cell line adaptation, due to the possible impact of mutations on the safety and efficacy of cell therapy products
- Breakthrough approaches that are suitable for cell therapy manufacturing, including some already proven to work for mAB manufacturing, will be discussed
